KR20070054191A - 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법 - Google Patents

란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법 Download PDF

Info

Publication number
KR20070054191A
KR20070054191A KR1020077004213A KR20077004213A KR20070054191A KR 20070054191 A KR20070054191 A KR 20070054191A KR 1020077004213 A KR1020077004213 A KR 1020077004213A KR 20077004213 A KR20077004213 A KR 20077004213A KR 20070054191 A KR20070054191 A KR 20070054191A
Authority
KR
South Korea
Prior art keywords
lanthanum
ckd
hydroxy carbonate
carbonate
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077004213A
Other languages
English (en)
Korean (ko)
Inventor
조세핀 크리스틴 페르디난도
데이빗 길모어
Original Assignee
샤이어 파마세우티컬, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 샤이어 파마세우티컬, 인크. filed Critical 샤이어 파마세우티컬, 인크.
Publication of KR20070054191A publication Critical patent/KR20070054191A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020077004213A 2004-07-27 2005-07-27 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법 Ceased KR20070054191A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59110504P 2004-07-27 2004-07-27
US60/591,105 2004-07-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001877A Division KR101072196B1 (ko) 2004-07-27 2005-07-27 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법

Publications (1)

Publication Number Publication Date
KR20070054191A true KR20070054191A (ko) 2007-05-28

Family

ID=35787449

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077004213A Ceased KR20070054191A (ko) 2004-07-27 2005-07-27 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법
KR1020097001877A Expired - Fee Related KR101072196B1 (ko) 2004-07-27 2005-07-27 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097001877A Expired - Fee Related KR101072196B1 (ko) 2004-07-27 2005-07-27 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법

Country Status (14)

Country Link
US (1) US20060153932A1 (https=)
EP (1) EP1708723A4 (https=)
JP (1) JP4869229B2 (https=)
KR (2) KR20070054191A (https=)
CN (1) CN101018555A (https=)
AU (1) AU2005269362B2 (https=)
BR (1) BRPI0513603A (https=)
CA (1) CA2574450C (https=)
EA (1) EA010980B1 (https=)
MX (1) MX2007001114A (https=)
NO (1) NO20070906L (https=)
NZ (1) NZ552861A (https=)
WO (1) WO2006015055A1 (https=)
ZA (1) ZA200701707B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095055A1 (ko) * 2015-12-01 2017-06-08 김배용 생리활성물질 복합체, 이의 제조방법 및 이를 포함한 화장료 조성물

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
EP1852695B1 (en) * 2006-05-05 2011-10-26 Shire International Licensing B.V. Assay for lanthanum hydroxy carbonate
US8961917B2 (en) * 2010-05-12 2015-02-24 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
GB201501000D0 (en) * 2015-01-21 2015-03-04 Univ Edinburgh Lanthanum thiosulfate and methods of preparation of the same
WO2017072256A1 (en) * 2015-10-27 2017-05-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Nicotinamide for lowering phosphate levels in hyperphosphatemia
KR101684289B1 (ko) 2016-05-17 2016-12-09 한국식품연구원 락토바실러스 sp. KCCM 11826P 균주를 이용한 고인산혈증 예방, 만성 신장질환 치료용 약학조성물 및 건강기능성 식품
US10322409B1 (en) * 2018-03-05 2019-06-18 King Fahd University Of Petroleum And Minerals Low temperature hydrothermal method for the preparation of LaCO3OH nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4592082A (en) * 1984-08-10 1986-05-27 The United States Of America As Represented By The United States Department Of Energy Quantitative determination of mineral composition by powder X-ray diffraction
CA2117351C (en) * 1992-01-13 1998-03-03 Julian Belknap Lo Preparation of tablets of increased strength
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
US5435986A (en) * 1994-08-30 1995-07-25 Industrial Technology Research Institute Method for preparing high purity aluminum hydroxide
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
AU782304B2 (en) * 1999-09-02 2005-07-14 Acologix, Inc. Methods and compositions for reducing serum phosphate levels
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
DK1389102T3 (da) * 2001-04-23 2011-06-06 Shire Int Licensing Bv Anvendelse af lanthancarbonat til forebyggelse af nyresten
US7469036B2 (en) * 2002-04-19 2008-12-23 Los Alamos National Security, Llc Analysis of macromolecules, ligands and macromolecule-ligand complexes
AU2003229437A1 (en) * 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095055A1 (ko) * 2015-12-01 2017-06-08 김배용 생리활성물질 복합체, 이의 제조방법 및 이를 포함한 화장료 조성물
US10835461B2 (en) 2015-12-01 2020-11-17 Bae Yong Kim Bio-active material composite, preparing method thereof and cosmetic composition containing the same

Also Published As

Publication number Publication date
ZA200701707B (en) 2008-10-29
CN101018555A (zh) 2007-08-15
MX2007001114A (es) 2007-07-11
AU2005269362A1 (en) 2006-02-09
CA2574450C (en) 2011-07-19
NO20070906L (no) 2007-04-23
WO2006015055A1 (en) 2006-02-09
US20060153932A1 (en) 2006-07-13
EP1708723A1 (en) 2006-10-11
EA200700273A1 (ru) 2007-08-31
JP4869229B2 (ja) 2012-02-08
KR101072196B1 (ko) 2011-10-10
EA010980B1 (ru) 2008-12-30
KR20090023743A (ko) 2009-03-05
CA2574450A1 (en) 2006-02-09
JP2008508297A (ja) 2008-03-21
AU2005269362B2 (en) 2010-08-12
BRPI0513603A (pt) 2008-05-13
NZ552861A (en) 2010-11-26
EP1708723A4 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
KR101072196B1 (ko) 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법
US20250144065A1 (en) Method of treating chronic kidney disease
Emmett et al. Calcium acetate control of serum phosphorus in hemodialysis patients
US20100119602A1 (en) Phosphate binder with reduced pill burden
JP2008508297A5 (https=)
KR20000069414A (ko) 신부전의 치료 방법
US8129430B2 (en) Method of reducing phosphate nephropathy in a mammal
KR0145715B1 (ko) 세포보호성 약제로서의 n-아세틸글루코사민을 함유하는 조성물
EP1768748B2 (en) Compositions comprising strontium and vitamin d and uses thereof
EP1785142B1 (en) Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
Birck et al. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study.
US6887897B2 (en) Calcium glutarate supplement and phosphorus binder
WO2003094933A2 (en) Use of lanthanum for the treatment of hypercalcemia and bone metastasis
CN1315174A (zh) 治疗肾衰的药物组合物
HK1102545B (en) Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds
CN107595829B (zh) 一种防治肾性骨营养不良的组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070801

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080421

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080930

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080421

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20081230

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080930

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20100330

Appeal identifier: 2008101014062

Request date: 20081230

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090129

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20081230

Effective date: 20100330

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20100330

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20081230

Decision date: 20100330

Appeal identifier: 2008101014062